PMID- 29484571
OWN - NLM
STAT- MEDLINE
DCOM- 20180522
LR  - 20181113
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 63
IP  - 4
DP  - 2018 Apr
TI  - Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory 
      Bowel Disease.
PG  - 825-833
LID - 10.1007/s10620-018-4971-1 [doi]
AB  - BACKGROUND: Approximately 15-20% of ulcerative colitis patients and 20-40% of
      those with Crohn's disease experience extraintestinal manifestations (EIMs) of
      their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs
      affecting multiple organs that variably correlate with intestinal disease
      activity. Vedolizumab is a monoclonal antibody for the treatment of IBD with a
      gut-selective mechanism of action. AIMS: This report evaluates whether
      vedolizumab is an effective treatment of EIMs, given its gut-specific mechanism
      of action. METHODS: We report 8 case studies of patients with various EIMs,
      including pyoderma gangrenosum, peripheral arthralgia/arthritis, axial
      arthropathies, erythema nodosum, and uveitis, who received vedolizumab therapy.
      RESULTS: Vedolizumab therapy was effective for pyoderma gangrenosum in ulcerative
      colitis, uveitis, erythema nodosum, polyarticular arthropathy, and ankylosing
      spondylitis/sacroiliitis but did not provide sustained benefit for the treatment 
      of pyoderma gangrenosum in a patient with Crohn's disease. CONCLUSIONS: These
      cases demonstrate the potential of vedolizumab as a treatment of EIMs in patients
      with IBD.
FAU - Fleisher, Mark
AU  - Fleisher M
AD  - Borland-Groover Clinic, Jacksonville, FL, USA.
FAU - Marsal, Jan
AU  - Marsal J
AD  - Lund University, Lund, Sweden.
FAU - Lee, Scott D
AU  - Lee SD
AD  - University of Washington, Seattle, WA, USA.
FAU - Frado, Laura E
AU  - Frado LE
AD  - Mount Sinai Hospital, New York, NY, USA.
FAU - Parian, Alyssa
AU  - Parian A
AD  - Johns Hopkins Hospital, Baltimore, MD, USA.
FAU - Korelitz, Burton I
AU  - Korelitz BI
AD  - Division of Gastroenterology, Department of Medicine, Lenox Hill Hospital, New
      York, NY, 10075, USA.
FAU - Feagan, Brian G
AU  - Feagan BG
AD  - Robarts Clinical Trials, Robarts Research Institute, Western University, 100
      Dundas Street, Suite 200, London, ON, N6A 5B6, Canada.
      Brian.feagan@robartsinc.com.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180226
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Gastrointestinal Agents)
RN  - 9RV78Q2002 (vedolizumab)
SB  - AIM
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Female
MH  - Gastrointestinal Agents/*therapeutic use
MH  - Humans
MH  - Inflammatory Bowel Diseases/*complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Young Adult
PMC - PMC5854745
OTO - NOTNLM
OT  - *Crohn's disease
OT  - *Extraintestinal manifestations
OT  - *Inflammatory bowel disease
OT  - *Ulcerative colitis
EDAT- 2018/02/28 06:00
MHDA- 2018/05/23 06:00
CRDT- 2018/02/28 06:00
PHST- 2017/10/03 00:00 [received]
PHST- 2018/02/08 00:00 [accepted]
PHST- 2018/02/28 06:00 [pubmed]
PHST- 2018/05/23 06:00 [medline]
PHST- 2018/02/28 06:00 [entrez]
AID - 10.1007/s10620-018-4971-1 [doi]
AID - 10.1007/s10620-018-4971-1 [pii]
PST - ppublish
SO  - Dig Dis Sci. 2018 Apr;63(4):825-833. doi: 10.1007/s10620-018-4971-1. Epub 2018
      Feb 26.